

*Unless otherwise defined herein, capitalised terms in this announcement shall have the same meanings as those defined in the prospectus dated Wednesday, June 24, 2020 (the “**Prospectus**”) issued by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”).*

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**SEHK**”) and Hong Kong Securities Clearing Company Limited (the “**CC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Company, the Hong Kong Public Offering and the International Offering described below before deciding whether or not to invest in the H Shares thereby offered.

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia) or any other jurisdiction where such distribution is prohibited by law. This announcement does not constitute or form a part of any offer to sell or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions. The H Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”), or any state securities laws of the United States. The Offer Shares may not be offered, sold, pledged or transferred within the United States, except pursuant to an effective registration statement or in accordance with an available exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. There will be no public offer of securities of the Company in the United States.*

The obligations of the Hong Kong Underwriters under the Hong Kong Underwriting Agreement to subscribe or purchase, and to procure applicants for the subscription or purchase of, the Hong Kong Offer Shares, are subject to termination by the Joint Global Coordinators (for themselves and on behalf of the Hong Kong Underwriters) if certain grounds arise prior to 8:00 a.m. on the day that trading in the Offer Shares commences on the Stock Exchange, which is expected to be Wednesday, July 8, 2020. Such grounds are set out in the section headed “Underwriting” in the Prospectus. It is important that you refer to that section for further details.



(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9989)

PRICE DETERMINATION

Reference is made to the announcement of the Company dated June 24, 2020, the Prospectus and the related Application Forms in relation to the Hong Kong Public Offering.

The Offer Price has been determined at HK\$18.40 per H Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%) on June 30, 2020.

The Company expects to announce the level of indication of interest in the International Offering, the basis of allocation and the level of applications under the Hong Kong Public Offering (i) on the website of the Stock Exchange (www.hkexnews.hk); and (ii) on the Company's website (www.hepalink.com) on Tuesday, July 7, 2020. The results of allocations and the Hong Kong identity card/passport/Hong Kong business registration numbers of successful applicants under the Hong Kong Public Offering will be available at the times and date and in the manner specified in the section headed "How to Apply for the Hong Kong Offer Shares — 11. Publication of Results" in the Prospectus.

Dealings in the H Shares on the Stock Exchange are expected to commence at 9:00 a.m. on Wednesday, July 8, 2020.

On behalf of the Board of Directors
Shen hen Hepalink Pharmaceutical Group Co., Ltd.
Li LI
Chairman

Hong Kong, Thursday, July 2, 2020

As at the date of this announcement, the board of directors of the Company comprises Mr. Li Li, Ms. Li Tan, Mr. Shan Yu, Mr. Sun Xuan and Mr. Bu Haihua as executive Directors; and Dr. Lu Chuan, Mr. Chen Junfa, and Mr. Wang Zhaohui as independent non-executive Directors.